SIG001

Phase 1Biologic

PPeking University

SIG001 is one of 7 biologic programs targeting Antibody. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AntibodyNot yet recruiting

AntibodyPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Antibody

#DrugCompanyPhaseTrials

BEYFORTUS

Sanofi

Phase 3

1 2

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 2

2 3

Sylvant

RRECORDATI GROUP

Phase 1

1 4

SIG001

PPeking University

Phase 1

1 5

Iodine-131 Anti-B1 Antibody

GSK

Preclinical

1 6

CID-103

CCASI Pharmaceuticals, Inc.

Preclinical

1 7

Gammaglobulin

UUniversity of Aarhus

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Antibody

NCT07486700

Clinical

Trials by Indication[1]

Antibody1 trial

The Phase I Study of SIG001 Antibody on Cancer Therapy.

Not yet recruiting·PPeking University·Phase 1·NCT07486700·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SIG001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SIG001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SIG001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPeking University

SIG001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Antibody1 trial

References

Drug Info

Quick Facts

Related News